glp 1 agonist with dpp 4 inhibitor Frontiers The DPP-4 inhibitor linagliptin and
Description
doi: 10.3390/ijms242115645
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS Semaglutide and Tirzepatide have been a source of disruption in the overall healthcare market
First, transparent communication is crucial
Despite the small sample size (only 10 patients), the observed benefits suggest that GLP-1RAs could have a therapeutic role in PsA through inflammation reduction, similar to what had been observed in PsO (61)
Kieffer TJ, McIntosh CH, Pederson RA
